An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors (NCT07293754)
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Who can join: Review the eligibility criteria below.
Location: START Midwest — Grand Rapids, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- START Midwest — Grand Rapids, Michigan
📞 Contact the Study Coordinator
Phone: (616) 954-5561
Email: jacob.goldberg@startresearch.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Malignant Solid Tumor
- Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors — Grand Rapids, Michigan
- A First in Human Study of PLT012 in Participants With Solid Tumor Cancers — Los Angeles, California
Explore by condition: All Advanced Malignant Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.